Ambry Genetics Prevails in Preliminary Injunction Motion Filed By Myriad Genetics

March 11, 2014

FOR IMMEDIATE RELEASE

Ambry Genetics
1 Enterprise
Aliso Viejo, CA 92656

Aliso Viejo, Calif. – March 10, 2014 – Ambry Genetics (“Ambry”), the worldwide leader in hereditary cancer testing, announced today that it has successfully defended itself against the preliminary injunction motion filed on July 9, 2013 by Myriad Genetics (“Myriad”) and other plaintiffs in University of Utah Research Foundation et al. v. Ambry Genetics Corporation, Case No. 2:13-cv-00640-RJS, pending in the United States District Court for the District of Utah.

Since launching their BRCA product line on the day of the Supreme Court’s ruling against Myriad (June 13, 2013), Ambry has been widely embraced by physicians, genetic counselors and other medical professionals. Given today’s favorable ruling, Ambry will continue to offer all previously launched BRCA-related genetic testing products.

“Today’s win is a victory for the entire genetics community. We’ve all believed for years that products of nature should not be patentable and were thrilled with the Supreme Court ruling in June 2013 affirming this principle. We stood by our convictions after Myriad sued Ambry and are exhilarated by today’s ruling,” said Chief Executive Officer, Charles Dunlop. “Competition stemming from a free market drives all of us to improve and ultimately increases patient access to life-changing information. Our company has been providing innovative genetic testing and excellent service to children’s hospitals and cancer centers for the last 13 years and we are excited to see the industry evolve in this new era.”

Ambry Genetics is represented in the lawsuit by William Gaede and Eric Hagen of McDermott Will & Emery and Edgar Cataxinos of TraskBritt.


About Ambry Genetics ®

Ambry Genetics, as part of REALM IDx, Inc., excels at translating scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. Our unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means we are first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions. We care about what happens to real people, their families, and the people they love, and remain dedicated to providing them and their clinicians with deeper knowledge and fresh insights, so together they can make informed, potentially life-altering healthcare decisions.

Press Contact:
Brad Lotterman
press@ambrygen.com

Search Results

Start your search...